LAG3 and colonic neoplasm: In addition, the anti-LAG-3/PD-L1 mAb2 was also used to reduce tumor burden in the MC38 colon cancer model, and there were more tumor-free animals in the LAG-3/PD-L1 bispecific group than in the combined anti-LAG-3 and anti-PD-L1 groups, which was similar to the CT26 mouse colon cancer model [64].